All In Biotech

Drug Trial Radar · NCT05868876

A Phase Ia/Ib Open Label,Clinical Study Evaluating the Safety, Tolerability and Preliminary Efficacy of AK127 in Combination With AK104 in Patients With Advanced Malignant Tumors

Last checked: Nov 19, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

70

Actual

Start

Jul 26, 2023

Primary completion

Mar 4, 2026

Study completion Mar 4, 2026

Sponsor

Lead sponsor
AkesoIndustry
Sponsor type
Industry
First posted
May 22, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase Ia/Ib open label,clinical study evaluating the safety, tolerability and preliminary efficacy of AK127 in combination with AK104 in patients with advanced malignant tumors

Conditions

  • Advanced Malignant Tumors

Interventions

  • AK127 Q3W IV infusion ,AK104 10mg/kg Q3W IV infusionDrug

    AK127 is administered intravenously according to the frequency Q3W and different dosage of administration at different stages.AK104 is administered intravenously according to the frequency and dosage 10mg/kg Q3W.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and severity of adverse events(AE);Time frame: Up to approximately 2 years
  2. Incidence of serious adverse events(SAE);Time frame: Up to approximately 2 years
  3. Incidence of immune-related adverse events(irAE);Time frame: Up to approximately 2 years
  4. The incidence of suspected unexpected serious adverse reactions(SUSAR);Time frame: Up to approximately 2 years
  5. Incidence of dose-limiting toxicity(DLT);Time frame: Up to approximately 2 years
  6. Number of participants with clinically significant changes in laboratory assessment data as assessed by CTCAE v5.0.Time frame: Up to approximately 2 years
  7. AE that leads to the termination or suspension of treatment.Time frame: Up to approximately 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Tianjin Cancer Hospital

    Tianjin, Tianjin Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.